126 related articles for article (PubMed ID: 17278781)
1. [Plasminogenesis in blood of patients with chronic myeloproliferative syndromes].
Rość D; Kremplewska-Nalezyta E; Gadomska G; Drewniak W; Koczubik W
Pol Arch Med Wewn; 2006 Jan; 115(1):23-8. PubMed ID: 17278781
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
3. Profile of blood coagulation and fibrinolysis in chronic myeloproliferative disorders.
Takahashi H; Hattori A; Shibata A
Tohoku J Exp Med; 1982 Sep; 138(1):71-80. PubMed ID: 6959382
[TBL] [Abstract][Full Text] [Related]
4. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.
Villmow T; Kemkes-Matthes B; Matzdorff AC
Thromb Res; 2002 Nov; 108(2-3):139-45. PubMed ID: 12590950
[TBL] [Abstract][Full Text] [Related]
5. Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders.
Parise P; Huybrechts E; Grasselli S; Falcinelli F; Nenci GG; Gresele P; Vermylen J
Acta Haematol; 1991; 85(2):88-92. PubMed ID: 1902615
[TBL] [Abstract][Full Text] [Related]
6. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms.
Huang K; Mo Q; Liao C; Feng S; Liu G; Jiang D; Lei P
Clin Exp Med; 2024 May; 24(1):107. PubMed ID: 38776019
[TBL] [Abstract][Full Text] [Related]
8. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
[TBL] [Abstract][Full Text] [Related]
9. [Thrombinogenesis in chronic myeloproliferative syndromes].
Rość D; Kremplewska-Nalezyta E; Gadomska G; Kowalewska A; Buczkowska E
Pol Merkur Lekarski; 2006 Jun; 20(120):717-20. PubMed ID: 17007278
[TBL] [Abstract][Full Text] [Related]
10. Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders.
Meschengieser S; Blanco A; Woods A; Maugeri N; Fernandez J; Dupont J; Lazzari MA
Thromb Res; 1987 Nov; 48(3):311-9. PubMed ID: 3501618
[TBL] [Abstract][Full Text] [Related]
11. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
12. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
13. Study of fibrinolytic parameters in different types of polycythemia.
Lugassy G; Filin I
Am J Hematol; 1999 Mar; 60(3):196-9. PubMed ID: 10072110
[TBL] [Abstract][Full Text] [Related]
14. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
15. [Fibrinolysis parameters: plasmin-alpha2 antiplasmin complexes (PAP) and D-dimers in acute coronary syndromes without ST segment elevation].
Grabarczyk E; Wodyńska T; Kotschy M
Pol Merkur Lekarski; 2004 Dec; 17(102):555-7. PubMed ID: 15771120
[TBL] [Abstract][Full Text] [Related]
16. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
17. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.
Strati P; Bose P; Lyle L; Gaw K; Zhou L; Pierce SA; Huynh-Lu J; Hirsch-Ginsberg CF; Bueso-Mendoza DE; Bueso-Ramos CE; Verstovsek S
Ann Hematol; 2017 May; 96(5):733-738. PubMed ID: 28247057
[TBL] [Abstract][Full Text] [Related]
18. Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Hsu HC; Tan LY; Au LC; Lee YM; Lieu CH; Tsai WH; You JY; Liu MD; Ho CK
J Lab Clin Med; 2004 Feb; 143(2):125-9. PubMed ID: 14966468
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Wehmeier A; Fricke S; Scharf RE; Schneider W
Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Gersuk GM; Carmel R; Pattengale PK
Blood; 1989 Nov; 74(7):2330-4. PubMed ID: 2804368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]